BioPharmSignal logoBioPharmSignal

Biotech News

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

MannKind (MNKD)MannKindEarnings

Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza ® following FDA approval FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKD Positive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement

Related news

MNKDMannKind2026-07-28 20:01 EST

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

MNKDMannKind2026-05-06 20:01 EST

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

ALGSAligos Therapeutics2026-08-06 12:00 EST

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

LXRXLexicon Pharmaceuticals2026-08-06 11:30 EST

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

NAMSNewAmsterdam Pharma2026-08-05 11:00 EST

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

RYTMRhythm Pharmaceuticals2026-08-04 11:01 EST

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

VKTXViking Therapeutics2026-07-29 20:05 EST

Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

CVRXCVRx2026-07-23 20:30 EST

CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

ALTAltimmune2026-08-05 12:00 EST

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

View all latest news

MannKind

Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...

Recent company news

MNKDMannKind2026-08-05 20:01 EST

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

MNKDMannKind2026-07-29 10:30 EST

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

MNKDMannKind2026-07-28 20:01 EST

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

MNKDMannKind2026-07-24 10:35 EST

MannKind Announces $50 Million Private Placement

MNKDMannKind2026-07-24 10:30 EST

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

Stock data

Close
3.89 USD
Market cap
1.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States